Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial.

This phase 2 trial assessed the combination of transarterial chemoembolization (TACE) with atezolizumab and bevacizumab in 45 patients with intermediate-stage hepatocellular carcinoma (HCC).

Over a median follow-up of 26.7 months, the results were:

• Objective response rate (ORR): 47% per RECIST v1.1 and 67% per mRECIST
• Median progression-free survival (PFS): 17.9 months
• Overall survival (OS): 33.0 months
• Disease control rates: High, ranging from 87% to 91%, with durable responses

Adverse events occurred in nearly all patients, with 20 experiencing grade 3-4 events. There were no treatment-related deaths.

The study concludes that TACE combined with atezolizumab and bevacizumab is safe, feasible, and shows promising efficacy for intermediate-stage HCC, warranting further investigation.